SUBSCRIBE
SUBSCRIBE

BioSpace Insights

The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.

Insights
Nordic biotech’s next act: From fragmentation to global force
In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage.
July 23, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
SUPPORTED BY AMPLITY
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
This webinar provides an assessment of recent job market activity across biopharma and explores how companies approaching commercial readiness or building out sales and marketing teams can navigate today’s hiring trends.
July 22, 2026
 · 
1 min read
 · 
BioSpace Insights
Insights
The future of pain relief: Exploring opioid alternatives
In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today, and how non-opioid mechanisms to regenerative therapies could reshape the future of treatment.
July 16, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Job Trends
Report: Biopharma Job Market Report Q2 2026
Gain the latest insights into the biopharma hiring landscape with BioSpace’s Biopharma Job Market Report Q2 2026. Explore the trends shaping talent acquisition, from rising job postings and sustained R&D hiring to the market activity signaling stronger hiring demand ahead.
July 13, 2026
 · 
1 min read
 · 
BioSpace Insights
Insights
From sequence to scale: Gene editing’s new era in biologics manufacturing
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
July 10, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
IN PARTNERSHIP WITH CERTARA
Webinar: Streamlining Nonclinical Development with FDA NAMs
FDA’s draft guidance on the validation of non-animal methods (NAMs) is reshaping how nonclinical programs are designed and justified. This webinar explores how sponsors can apply NAMs to streamline development, improve human relevance, and support IND decision-making within a weight-of-evidence framework.
July 1, 2026
 · 
1 min read
 · 
BioSpace Insights
A man and woman on opposite edges of a large chat bubble
Insights
Golden Triangle still dominates, but talent and capital gaps slow biotech growth
The U.K.’s core biotech cluster continues to produce world‑class science, but investors say limited talent mobility, uneven regional growth and tightening early‑ and mid‑stage capital are slowing the country’s ability to scale new companies.
July 1, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at M Ventures and Maina Bhaman, partner at Sofinnova Partners. We explore the UK biotech ecosystem: from the Golden Triangle’s evolving role to the challenges of scaling companies, unlocking pension capital and staying globally competitive.
June 25, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
A gloved hand carefully collecting blood from a test tube while a microscope stands nearby, showcasing the intricate process of conducting lab blood tests for health analysis
Insights
Labs see rising demand for nitrosamine, topical performance and microbiome testing
Recent BioSpace industry conference conversations point to sponsors pushing earlier on safety, quality and performance data, leading to demand for nitrosamine analysis, IVRT/IVPT and microbiome database capabilities.
June 25, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
From fragile skin to living medicine: Lessons from RDEB
In this episode of Denatured, you’ll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We explore how recessive dystrophic epidermolysis bullosa has become a defining case study for gene and cell therapy and what this ultra‑rare disease reveals about the future scalability of advanced therapies.
June 18, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
A 3D rendering of an old, simple arch bridge connecting two groups of stacked gold coins. It represents financial support, fund flow, investment, or bridging a monetary gap.
Insights
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
Strong science, lower costs and growing capital networks are putting Spain and Portugal on the biotech investment map, even as structural bottlenecks persist, according to two investors.
June 12, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Insights
Portugal, Spain and the new biotech frontier
In this episode of Denatured, you’ll be hearing from Hannah Franklin, associate at Biovance Capital and Pablo Gabriel Cironi Lopez, director of life science investment at Caixa Capital Risc as they discuss the rise of Southern Europe’s biotech ecosystem.
June 11, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Insights
Rethinking hair loss treatment
In this episode of Denatured, you’ll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients.
June 4, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Two man climbing on a rock. Work smart not hard concept. This is a 3d render illustration.
Insights
France’s biotech ambition is strong but its scale-up engine still needs work
Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but turning research into investable companies remains a challenge.
June 2, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
France’s biotech ecosystem: science, capital and scale
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech.
May 28, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker